GlobeNewswire Inc | Oct 7, 2020 08:05AM EDT

October 07, 2020

MONMOUTH JUNCTION, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), alate clinical-stagebiopharmaceutical companyworking to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikgfor use in retinalindications, today announced that Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics, will participate at the BIO Investor Forum Digital taking place on October 13-15, 2020.

The Outlook Therapeutics corporate presentation will be available on-demand during the conference to those registered to attend. Additionally, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend. Interested parties can request a meeting through the conference portal. For additional information about the conference, please visit the conference website.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:

Media Inquiries:Jessica MorrisAccount ExecutiveLaVoie Health ScienceT: 857.701.9731jmorris@lavoiehealthscience.com

Investor Inquiries:Jenene ThomasChief Executive OfficerJTC Team, LLCT: 833.475.8247OTLK@jtcir.com